急性脑出血收缩压时间轨迹与结局:ATACH-2 试验队列
BACKGROUND: To highlight the heterogeneity of acute temporal blood pressure (BP) changes in the ATACH-2 trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage-2) and associations with the outcomes of intracerebral hemorrhage.…
要点
- 基于组的轨迹模型识别出 4 种收缩压轨迹:中、中至低、高至低、高。
- 高至低收缩压组较中至低组 3 个月死亡或残疾风险升高(aOR 2.29)。
- 高至低收缩压组较中至低组急性肾损伤风险升高(aOR 3.50)。
核心结论
- 采用基于组的轨迹模型进行数据驱动观察可能有助于阐明降压治疗、收缩压时间变化与急性脑出血结局之间的关系。
研究设计与样本
- 采用基于组的轨迹模型分析随机后 24 小时内每小时最大收缩压的时间变化。
主要发现
- 基于组的轨迹模型识别出 4 个收缩压轨迹组:中收缩压组(入院时约 190 mm Hg 降至随机后 150-160 mm Hg,n=298)、中至低收缩压组(约 190 mm Hg 降至 <140 mm Hg,n=395)、高至低收缩压组(>210 mm Hg 降至 <140 mm Hg,n=134)、高收缩压组(>210 mm Hg 降至 160-170 mm Hg,n=173)。
- 强化治疗患者在各组中分别占 11.1%、88.6%、85.1%、1.7%。
- 与中至低收缩压组相比,高至低收缩压组 3 个月死亡或残疾风险升高(调整比值比 2.29 [95%CI 1.24-4.26]),急性肾损伤风险升高(调整比值比 3.50 [95%CI 1.83-6.69])。
- 高至低收缩压组神经功能恶化无增加(调整比值比 0.48 [95%CI 0.20-1.13])。
- 中收缩压组和高收缩压组在这些结局上无显著风险差异。
关键数值与推荐
- 结局包括 3 个月死亡或残疾(改良 Rankin 量表评分 4-6 分)、24 小时内神经功能恶化(格拉斯哥昏迷量表评分下降≥2 分或美国国立卫生研究院卒中量表评分增加≥4 分)、7 天内急性肾损伤(48 小时内血清肌酐升高≥0.3 mg/dL 或较基线增加≥1.5 倍)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To highlight the heterogeneity of acute temporal blood pressure (BP) changes in the ATACH-2 trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage-2) and associations with the outcomes of intracerebral hemorrhage. METHODS: One thousand patients with acute intracerebral hemorrhage, who had been randomized to intensive (110-139 mm Hg) or standard (140-179 mm Hg) systolic BP (SBP) lowering with intravenous nicardipine in ATACH-2 from 2011 to 2015, were analyzed about temporal changes in hourly maximum SBP up to 24 hours after randomization using group-based trajectory modeling. Outcomes included death or disability (modified Rankin Scale score 4-6) at 3 months, neurological deterioration within 24 hours (≥2-point decrease in Glasgow Coma Scale score or ≥4-point increase in National Institutes of Health Stroke Scale score), and acute kidney injury (≥0.3 mg/dL within 48 hours or ≥1.5-fold increase in serum creatinine) within 7 days after onset. RESULTS: Group-based trajectory modeling revealed 4 SBP trajectory groups: moderate SBP (from ≈190 mm Hg at hospital arrival to 150-160 mm Hg after randomization; n=298), moderate-to-low SBP (from ≈190 mm Hg to <140 mm Hg; n=395), high-to-low SBP (from >210 mm Hg to <140 mm Hg; n=134), and high SBP (from >210 mm Hg to 160-170 mm Hg; n=173). Patients with intensive treatment accounted for 11.1%, 88.6%, 85.1%, and 1.7% of each group, respectively. Compared with the moderate-to-low SBP group, the high-to-low SBP group showed increased risks of death or disability at 3 months (adjusted odds ratio, 2.29 [95% CI, 1.24-4.26]) and acute kidney injury (adjusted odds ratio, 3.50 [95% CI, 1.83-6.69]), while no increase in neurological deterioration was seen in this group (adjusted odds ratio, 0.48 [95% CI, 0.20-1.13]). The moderate SBP and high SBP groups showed no significant risk differences for such outcomes. CONCLUSIONS: Data-driven observation using a group-based trajectory modeling approach may be useful to clarify the relationship between antihypertensive treatment, temporal SBP changes, and outcomes in acute intracerebral hemorrhage. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01176565.
引用
- Tanaka K, Koga M, Fukuda-Doi M, et al. Temporal Trajectory of Systolic Blood Pressure and Outcomes in Acute Intracerebral Hemorrhage: ATACH-2 Trial Cohort. Stroke. 2022. PMID: 35400202. doi:10.1161/STROKEAHA.121.037186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。